Malignant Lymphoma Market Share

Malignant Lymphoma Market Overview

The malignant lymphoma market is anticipated to reach USD 8,365.4 Million by 2030 at 6.7% CAGR during the forecast period 2022-2030. Lymphomas are common forms of blood cancer and a few individuals in the general population suffer from this type of cancer. The lymphatic systems run through all parts of the body. Cancer that starts developing in any part of the body’s lymphatic system is called lymphoma. If that lymphoma can spread to other body parts, then it is called malignant lymphoma. Swollen glands are a common symptom of lymphoma. Compared to women, men are more prone to this disease. Worldwide, the malignant lymphoma market is rapidly growing. If the treatment is not conducted perfectly, the patient may have deadly outcomes and contribute to a high mortality rate.

Several biopharmaceuticals industry players like Amgen and Spectrum Pharmaceuticals are rising interested in the development of new products. Due to the rising number of individuals suffering from malignant lymphoma, there is a surge in the development of new treatment products. If the disease is in an advanced stage and harder to treat, then the advanced and altered treatment course is required which further raises the demand for cutting-edge and advanced therapies. The American Cancer Society report states that in 2020 nearly 77,240 individuals will undergo a diagnosis of non-Hodgkin lymphoma.

COVID-19 Analysis:

Due to the COVID-19 pandemic, most of the countries are suffered from a lack of treatment and bear a lot of burden on both their economy and healthcare systems at a time. As the hospitals are filled with corona patients and due to the limitations to visit the hospitals, the lymphomas patients had an additional risk by not receiving the required diagnostic procedures and treatment. Many guidelines are published recently to help dermatologists choose the right approach in this pandemic. Few countries do not apply to these guidelines due to the lockdown implementation and lack of enough resources for implementing the plan. Hence the pandemic is negatively impacted the malignant lymphoma market growth. After reducing the corona cases and lifting of lockdown, there is a rise in market growth rapidly.

A communication made by Eli Lilly and Company (NYSE: LLY) in December 2023 stated that the drug has been approved by FDA for Jaypirca® (pirtobrutinib, 100 mg & 50 mg tablets) to be used in adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapies including a BTK inhibitor and a BCL-2 inhibitor. The approval was based on ORR and DOR from an open-label, single-arm trial done in various countries known as the BRUIN phase 1/2 study. However, confirmation of clinical benefits must come from a confirmatory trial.

By January 2024, CAR-T therapies had not yet been manufactured for years; this was one drawback of such promising treatments. Nevertheless, Gilead Sciences has now been given a fresh endorsement by the FDA, which means that Yescarta will be produced with less treatment time for patients. According to the Kite Pharma unit, which informed us about the matter, such approval also implies modification in the manufacturing process of Yescarta by the FDA. Chris McDonald—Kite’s Chief Technical Operations Officer, Confirms Approval to FiercePharma—revealed that it would now take a minimum of seven days down from five days on average for Kite to produce each batch of CAR-T cell product used in Yescarta. Because of this reduced timeline for producing the drug candidates, Kite expects median start-to-end turnaround times between the T-cell collection and the final product release to be shortened from sixteen days currently to fourteen days only.

In August 2023, A wholly owned entity of CVS Health® that works with biosimilar manufacturers to market and/or co-develop biosimilars (an FDA-approved biologic medication that is highly similar to, and has no clinically meaningful differences from, a biologic medicine already approved by the FDA) specifically for the U.S. pharmaceutical industry was launched called Cordavis. The Cordavis products will be FDA-approved, high quality, and easy for patients to use, and they will help ensure a consistent long-term supply of affordable biosimilars. With the evolving picture in the U.S. pharmaceuticals arena, biosimilars offer employers and consumers one of their most significant chances at reducing drug costs in an otherwise expensive health system.

Malignant Lymphoma Market Trends

Drivers:

Increasing the clinical trials for developing the new drug candidates for various forms of lymphomas specifically for the harder treatment forms is anticipated to accelerate the growth of the market. The growing involvement of major companies in research and development leads to strong pipeline candidates that may propel market growth in the forecast period.

The rising prevalence of all forms of cancers including other types of blood cancers is one of the key driving factors of the market growth. The disease Lymphoma consists of a few blood cancer cases and there is a rise in demand for advanced products for the treatment. The essential thing was there are no clinical signs for the disease till it is in later stages. At this later stage, a more aggressive form of treatment is required for improved treatment outcomes. This factor is predicted to spur global market growth in the coming years.

Restraint:

Expensive treatment, complications related to drugs, low treatment options, and the presence of stringent regulatory guidelines are hampering the market growth.

Opportunities:

A rise in the number of improved diagnostic techniques and FDA approvals for therapy drugs may create an opportunity for key players to raise the market growth.

Challenges:

Due to the lower lymphoma treatment rates in emerging countries, the cost of the therapies becomes expensive which is reducing the number of individuals undergoing this treatment and most of the patients are not able to afford treatments like immunotherapies. Because the cost of these treatments is not affordable and accessible to poor people.

Study Objectives

To provide detailed information about the market structure along with many forecast segments and subsegments for the next 7 years.

To provide the factors that are impacting the growth of the market value.

 To evaluate the malignant lymphoma market industry analysis based on porter’s five force analysis, factors-price analysis, etc.

To provide previous and forecast revenue segments and sub-segments of the market revenue for the four main geographies.

To offer the country-level analysis of the current market size and future prospective. 

To provide country-level analysis of the global market industry growth by region, type, treatment, and application.

To provide a strategic profile of the prominent key competitors in the market, analyze their core competencies, and draw a global market growth landscape.

To track and analyze new product developments, joint ventures, strategic alliances, and global market research.

Malignant Lymphoma Market Segment Insights

The global malignant lymphoma market has been divided into three major segments based on type, region, and treatment.

Malignant Lymphoma Type Insigts

The malignant lymphoma based on the type is sectioned into two forms Hodgkin lymphoma and non-Hodgkin lymphoma. Out of these two segments, non-Hodgkin lymphoma type is predicted to account for the highest market share due to the majority of the lymphoma cases being non-Hodgkin lymphoma.

Malignant Lymphoma Treatment Insights

Based on the treatment, the malignant lymphoma market is partitioned into various segments like radiation therapy, chemotherapy, immunotherapy, stem cell therapy, and others. Among them, the immunotherapy segment is holding a significant share due to the higher revenue realization of these drugs. Immunotherapies named Yescarta, a dominant product in this treatment is introduced by Kite Pharma, Inc.

Malignant Lymphoma Regional Insights

The global malignant lymphoma based on the regions is classified into four major regions like Asia-Pacific, North America, Europe, and the Middle East & Africa. Among them, North America is holding the largest market share due to the high prevalence of lymphoma and high awareness regarding the treatment among the population.

Malignant Lymphoma Market Regional Analysis

Geographically, the malignant lymphoma market based on regions is categorized into four major regions such as Asia-Pacific, Europe, North America, and the Middle East & Africa. Out of these regions, North America is accounting for the largest malignant lymphoma market share due to the high prevalence of lymphoma, high awareness regarding lymphoma treatment among the patient population, higher rate of adoption of advanced lymphoma therapeutic drugs, and greater healthcare expenditure. Moreover, regular R&D by the industry players for the development of new drug candidates for lymphoma treatment in clinical trials is escalating the malignant lymphoma market growth.

Europe is dominating the second-largest market share due to the high number of individuals requiring treatment and high usage of advanced therapeutics. Asia-Pacific is expected to be the fastest-growing region in the review period for the approvals of key drugs like Kymriah in Japan for lymphoma treatment, the existence of a high potential patient population requiring treatment, and the under-tapped market potential in this region.  

Malignant Lymphoma Market Competitive Landscape

The prominent key players in the malignant lymphoma market outlook are the following:

• Abbott Laboratories


• Actelion Pharmaceuticals


• Allos Therapeutics


• Bristol-Myers Squibb Company


• Celgene Corporation


• Genmab


• Roche


• Inovio Pharmaceuticals


• Johnson & Johnson


• Onyx Pharmaceuticals


• Seattle Genetics


• ABIOGEN PHARMA S.P.A


• Aeterna Zentaris, Inc


• Astellas Pharma


• Eli Lilly and Company


• Merck & Co. Inc


• Novartis

Recent Developments

In May 2021, the popular enterpriser PerkinElmer, Inc is planning to acquire the Immunodiagnostic Systems Holdings PLC with an investment of nearly $155 million for expanding their overall diagnostics business.

In March 2020, one of the well-known companies Kura Oncology conducted a clinical trial for a pipeline candidate named tipifarnib which is used for the disease indication of peripheral T-cell lymphoma. Present, the clinical trial is in Phase-II and it received the fast track designation from the FDA.

In February 2021, the famous enterpriser Bristol Myers Squibb announced that their company received approval from the U.S Food and Drug Administration (FDA) for cancer immunotherapy as a treatment for adults who are having certain types of non-Hodgkin lymphoma.

Report Overview:

This global malignant lymphoma market research includes the Market Overview, COVID-19 analysis, Market Dynamics, Study Objectives, Segment Overview, Regional Analysis, Competitive Landscape, Recent developments, Segmentation Table, and FAQs. The market scenario includes the malignant lymphoma market drivers, restraints, challenges, and opportunities. The malignant lymphoma market forecast segments into three forms type, region, and treatment.